Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant
Stories and Music for Adolescent/Young Adult Resilience During Transplant (SMART)
6 other identifiers
interventional
118
1 country
3
Brief Summary
This randomized phase III trial is studying how well music therapy works compared to listening and discussing books on tape in improving quality of life in young patients undergoing stem cell transplant. Music therapy or book discussion may improve quality of life in patients undergoing stem cell transplant. It is not yet known whether music therapy is more effective than book discussion in improving quality of life in patients undergoing stem cell transplant.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for phase_3
Started Apr 2006
Longer than P75 for phase_3
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 21, 2006
CompletedFirst Posted
Study publicly available on registry
March 22, 2006
CompletedStudy Start
First participant enrolled
April 15, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 5, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
March 31, 2021
CompletedJuly 15, 2022
January 1, 2013
4.5 years
March 21, 2006
July 13, 2022
Conditions
Outcome Measures
Primary Outcomes (20)
Assess acute changes of Symptoms-related distress: Pain
Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on pain. Specifically, the instrument includes a 1-item pain numeric rating scale.
Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess acute changes of Symptoms-related distress: Anxiety
Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on anxiety. Specifically, the instrument includes a 5-item Anxiety scale.
Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess acute changes of Symptoms-related distress: Fatigue
Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measure capturing information on fatigue. Specifically, the instrument includes a 1-item fatigue visual analogue scale.
Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess acute changes of Symptoms-related distress: Mood
Illness-related distress will be measured by indicators of uncertainty in illness, symptom-related distress. Brief Symptoms Assessment is a self-reported measures capturing information on mood. Specifically, the instrument includes a 1-item mood scale.
Change from pre- and post-sessions 2, 4, and 6, baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess changes in uncertainty in illness as assessed by the Mishel Uncertainty in Illness Scale
Mishel Uncertainty in Illness Scale-Revised (MUIS-R) consists of two factors: Complexity and Ambiguity, with higher scores indicating a high level of uncertainty. Item responses are on a 5-point Likert-type scale (ranging from 5 = Strongly Agree to 1 = Strongly Disagree
Change from baseline, immediately after completion of study treatment and 100 days post-transplant
Assess changes in the use of defensive coping
Defensive Coping will be measured by three subscales of the Jalowiec Coping Scale-Revised (JCS): evasive, emotive, and fatalistic coping. JCS is a self-report, 0-3 point rating scale. The items are scored for both use and effectiveness.
Change from immediately after completion of study treatment and 100 days post-transplant
Assess changes in the use of positive coping
Three subscales of the Jalowiec Coping Scale-Revised will measure Positive Coping (JCS): confrontive, optimistic, and supportive.
Change from immediately after completion of study treatment and 100 days post-transplant
Assess changes in communication with family as assessed by Parent-Adolescent Communication
Parent Adolescent Communication (P-AC) self-report items are on 5-point Likert scales that assess adolescents' views regarding their perceptions and experience of communicating with each parent rated separately. The two subscales, Open Family Communication and Problems in Family Communication, respectively measure positive and negative aspects of communications within a family and are scored independently.
Change from baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess changes in adaptability or cohesion as assessed by FACES II
Family Adaptability and Cohesion Scale II (FACES II) is a self-report scale using Likert response scales and measuring the 2 factors: Adaptability or cohesion
Change from baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess changes in perceived social support from friends
Perceived Social Support from Friends (PSS-Fr) is a self-report scale using 3-point rating responses ranging from 0 to 2 designed to measure the extent to which individuals perceive that their needs for support, information, and feedback are fulfilled by friends.
Change from baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess changes in perceived social support from family
Perceived Social Support from Family (PSS-Fa) is a self-report, 3-point response (Yes, No, I don't know) scale, designed to measure the extent to which individuals perceive that their needs for support, information and feedback are fulfilled by family.
Change from baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess changes in perceived social support from healthcare providers
Perceived Social Support from Health Care Providers (PSS-HCP) is a self-report, 3-point rating scale adapted by Haase from items on the Perceived Social Support-Friends scales102 to correspond to health care provider relationships. Items indicate the extent to which individuals perceive their needs for support, information, and feedback are fulfilled by health care providers.
Change from baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess changes in Hope from stem cell transplantation (STC) experience:
Measured by indicators of hope. Herth Hope Index (HHI) items are on a 4-point scale, ranging from 1 (strongly disagree) to 4 (strongly agree); higher summative scores indicate greater hope.
Change from immediately after completion of study treatment, and 100 days post-transplant
Assess changes in Spiritual Perspective from stem cell transplantation (STC) experience
Measured by indicators spiritual perspective. Reed Spiritual Perspective Scale (RSPS) is a one-factor scale that measures the saliency of spiritual beliefs and behaviors in the respondent's life.157 The response format is a 6-point Likert scale anchored with words describing the frequency of behaviors.
Change from immediately after completion of study treatment, and 100 days post-transplant
Assess changes of Higher Resilience: Haase Adolescent Resilience in Cancer Scale
Haase Adolescent Resilience in Cancer Scale measures resilience related to illness. The scale uses a 6-point Likert-type scale ranging form: 1 (strongly disagree) to 4 (strongly agree); higher summative scores indicate greater resilience. Validity of the scales was found in predictive correlations with self-esteem, self-transcendence, confidence/mastery and quality of life. In Haase's preliminary studies, alpha reliability coefficients were 0.84 - 0.86.
Change from after completion of study treatment and 100 days post-transplant
Assess changes of Higher Resilience (self esteem, confidence, self-transcendence): NCS
Nowotny Confidence Subscale (NCS) of the Nowotny Hope Scale is a self-report of confidence in one's own ability, which uses a 4-point Likert response format of strongly agree to strongly disagree
Change from after completion of study treatment, and 100 days post-transplant
Assess changes of Higher Resilience (self esteem, confidence, self-transcendence): STS
Reed Self-Transcendence Scale (STS) assesses activities and perspectives individuals engage in to expand their boundaries via 4-point Likert response scales
Change from after completion of study treatment, and 100 days post-transplant
Assess changes in Higher Resilience (self esteem, confidence, self-transcendence): SES
Rosenberg Self-esteem Scale (SES) measures attitudes toward one's self. Responses are on a 4-point Likert scale.
Change from after completion of study treatment, and 100 days post-transplant
Assess changes in indicators of well-being and global quality of life: LASA Uniscale
Measured by indicators of well-being and global quality of life.LASA Uniscale is a global QOL self-report one-item instrument: "Please score how you feel your life has been affected by the state of your health (any disease or treatment) during the last week".160 The item is adopted from the Southwest Oncology Group protocol, which adapted the scale from a linear analogue to categorical format with 5 response categories ranging from extremely unpleasant to normal (no change).
Change from baseline, immediately after completion of study treatment, and 100 days post-transplant
Assess changes in indicators of well-being and global quality of life: IWB
Measured by indicators of well-being and global quality of life. Index of Well-being (IWB) is a semantic differential scale describing present life using adjective extremes such as discouraging/hopeful.
Change from baseline, immediately after completion of study treatment, and 100 days post-transplant
Secondary Outcomes (1)
Qualitatively describe the perception of helpfulness and meaningfulness of both the low-dose and TMV interventions for AYA and family members
100 days post-transplant
Study Arms (2)
Arm I (counseling)
ACTIVE COMPARATORPatients undergo six 1-hour sessions twice a week for 3 weeks with a trained counselor in which they choose up to 3 books on CD and listen to the book and/or discuss their impressions and thoughts about the contents with the counselor. Patients are provided with a portable CD player to listen to the books during their hospitalization.
Arm II (counseling and music therapy)
EXPERIMENTALPatients undergo six 1-hour sessions twice a week for 3 weeks with a music therapist, designed specifically for the pre-transplant and acute phase of treatment. Phases of patient participation include song writing, recording the song with a digital accompaniment track, completing a video layout worksheet, taking photos or making drawings for the video, viewing clip art and pictures on a computer, and sharing the final video with family members and hospital staff.
Interventions
Undergo books on tape therapy
Ancillary studies
Eligibility Criteria
You may qualify if:
- Diagnosis of an oncology condition requiring allogeneic or autologous transplantation
- Receiving or planning to receive a myeloablative treatment regimen and 1 of the following:
- Marrow transplantation
- Peripheral stem cell transplantation
- Cord blood stem cell transplantation
- Patients with cancers that do not usually occur in childhood/adolescent or young adult populations (e.g., breast or prostate cancer) are not eligible
- Able to read and speak English
- English does not need to be the primary language
- Able to participate in the sessions as evaluated for alertness and engagement by the music therapist
- No cognitive impairments that would make it difficult to participate in the intervention or complete questionnaires
- Not married and not a parent
- Concurrent therapy for pain control or relief of other symptoms allowed
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Children's Oncology Grouplead
- National Cancer Institute (NCI)collaborator
- National Institute of Nursing Research (NINR)collaborator
Study Sites (3)
Children's Healthcare of Atlanta - Egleston
Atlanta, Georgia, 30322, United States
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
Children's Oncology Group
Philadelphia, Pennsylvania, 19104, United States
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Joan E Haase
Children's Oncology Group
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 21, 2006
First Posted
March 22, 2006
Study Start
April 15, 2006
Primary Completion
October 5, 2010
Study Completion
March 31, 2021
Last Updated
July 15, 2022
Record last verified: 2013-01